MOORE CLINICAL RESEARCH, INC.

George W Monlux Jr, MD
Clinical Investigator

Curriculum Vitae

1104 Kyle Wood Lane, Brandon, Florida 33511 | 4257 West Kennedy Blvd, Tampa, FL 33609 | 11428 N 53rd Street, Temple Terrace, FL 33617
Office 813.948.7550 | MooreCR.com | Fax 813.948.7566

Research Experience:	
MOORE Clinical Research, Inc, Clinical Investigator	December 2018-Present

Education and Postdoctoral Training:	
Residency, Physical Medicine and Rehabilitation, Tufts School of Medicine, Boston MA	June 1996
Doctor of Medicine, University of Washington School of Medicine, Seattle, WA	June 1971
Experimental Pathology, University of Washington School of Medicine, Seattle, WA	June 1967
Bachelors in Zoology, University of Washington School of Medicine, Seattle, WA	June 1965

Licenses/Certifications/Memberships:	
State of Florida Medical License	January 2021
Board Certified, American Board of Family Medicine	April 2017
Bloodborne Pathogens & Biomedical Waste Management 29 CFR OSHA Regulations	December 2018
BLS for Healthcare Providers, American Heart Association	May 2021
ACLS for Healthcare Providers, American Heart Association	June 2021

Training:	
Adverse Event Collection and Reporting in Clinical Research	January 2019
Bloodborne Pathogens & Biomedical Waste Management	January 2019
Comprehensive SOP Review	January 2019
Responsible Conduct of Research, CITI Program	January 2019
Good Clinical Practice, NIH Training	January 2019
Human Subject Assurance Training	January 2019

Clinical Trial Experience:

- ACNE VULGARIS

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Clindamycin Phosphate Topical Lotion 1% (XXXX) to Clindamycin Phosphate Topical Lotion 1% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2019, Sub-Investigator

"A Multi-Center, Double-Blind, Randomized, Three-Arm, Placebo Controlled, Parallel-Group Study, Comparing Dapsone Gel, 7.5% (XXXX) to Aczone® (Dapsone) Gel, 7.5% (XXXX) and Both Active Treatments to A Placebo Control in the Treatment of Acne Vulgaris." 2019, Sub-Investigator

"A Phase 3 Multi-Center, Double-Blind, Randomized, Vehicle Controlled Study of XXXX in the Treatment of Acne Vulgaris." 2019, Sub-Investigator

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Clindamycin Phosphate Topical Gel 1% (XXXX) to Cleocin T (Clindamycin Phosphate Topical Gel 1%, XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2019, Principal Investigator

"A Phase 2, Randomized, Multicenter, Double-Blind, Vehicle Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of VB-1953 Topical Gel When Applied Daily for 12 Weeks in Subjects with Facial Acne Vulgaris for Treatment of Moderate to Severe Inflammatory Acne Vulgaris" 2019, Sub-Investigator

1104 Kyle Wood Lane, Brandon, Florida 33511 | 4257 West Kennedy Blvd, Tampa, FL 33609 | 11428 N 53rd Street, Temple Terrace, FL 33617
Office 813.948.7550 | MooreCR.com | Fax 813.948.7566

- Rosacea

"A Multi-Center, Open-Label, Long-Term Safety Study of XXXX to Evaluate the Safety of XXXX in Papulopustular Rosacea Patients." 2018, Sub-Investigator

- ATOPIC DERMATITIS

“A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Doxepin Hydrochloride Topical Cream, 5% (XXXX) to Doxepin Hydrochloride topical cream, 5% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Moderate Pruritis in Adults with Atopic Dermatitis.” 2019 Sub-Investigator

- ACTINIC KERATOSIS

"A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel Group Bioequivalence Study to Compare XXXX 5-FU Cream 5%, with Efudex (5-FU) Cream 5%, and Both Active Treatments to a Vehicle Control, in the Treatment of Actinic Keratosis." 2019, Sub-Investigator

- PSORIASIS

“A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Calciotriol and Betamethasone Dipropionate Topical Gel 0.005%/0.064% (XXXX) Dovobet® Gel (Calcipotriol and Betamethasone Dipropionate Gel) 0.005%/0.064% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Mild to Moderate Body Plaque Psoriasis Vulgaris.” 2019 Sub-Investigator

"A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with Randomized Withdrawal and Retreatment to Evaluate the Efficacy and Safety of XXXXX in Subjects with Moderate-to-Severe Plaque Psoriasis." 2018, Sub-Investigator

“A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients with Moderate-Severe Plaque Psoriasis.: 2018, Sub-Investigator

- SCALP PSORIASIS

“A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension 0.005%/0.064% (XXXX) to Talconex® (Calcipotriene Hydrate and Betamethasone Dipropionate) Topical Suspension 0.005%.0.064% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Scalp Psoriasis.” 2018, Sub-Investigator

- TINEA PEDIS

"A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Design, Multiple-Site Study to Evaluate the Therapeutics Equivalence of Ketoconazole Cream 2% (XXXX) to Ketoconazole 2% (XXXX) in the Treatment of Tinea Pedis." 2019, Principal Investigator

- INFLUENZA

“A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza.” 2018, Sub-Investigator